X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Cadila Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs CADILA HEALTHCARE - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES CADILA HEALTHCARE DIVIS LABORATORIES/
CADILA HEALTHCARE
 
P/E (TTM) x 30.0 32.8 91.5% View Chart
P/BV x 5.2 6.1 85.3% View Chart
Dividend Yield % 1.0 0.8 123.4%  

Financials

 DIVIS LABORATORIES   CADILA HEALTHCARE
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
CADILA HEALTHCARE
Mar-17
DIVIS LABORATORIES/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,222460 265.7%   
Low Rs784305 257.0%   
Sales per share (Unadj.) Rs153.192.1 166.2%  
Earnings per share (Unadj.) Rs39.914.8 269.6%  
Cash flow per share (Unadj.) Rs44.618.5 241.3%  
Dividends per share (Unadj.) Rs10.003.20 312.5%  
Dividend yield (eoy) %1.00.8 119.2%  
Book value per share (Unadj.) Rs201.868.0 296.8%  
Shares outstanding (eoy) m265.471,023.74 25.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.64.2 157.8%   
Avg P/E ratio x25.125.8 97.3%  
P/CF ratio (eoy) x22.520.7 108.7%  
Price / Book Value ratio x5.05.6 88.3%  
Dividend payout %25.021.6 115.9%   
Avg Mkt Cap Rs m266,266391,581 68.0%   
No. of employees `0009.716.9 57.8%   
Total wages/salary Rs m4,68715,002 31.2%   
Avg. sales/employee Rs Th4,175.05,594.5 74.6%   
Avg. wages/employee Rs Th481.5890.1 54.1%   
Avg. net profit/employee Rs Th1,089.3899.9 121.0%   
INCOME DATA
Net Sales Rs m40,64394,295 43.1%  
Other income Rs m7491,286 58.2%   
Total revenues Rs m41,39295,581 43.3%   
Gross profit Rs m14,46019,036 76.0%  
Depreciation Rs m1,2333,750 32.9%   
Interest Rs m23450 5.0%   
Profit before tax Rs m13,95316,122 86.5%   
Minority Interest Rs m0338 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3 0.0%   
Tax Rs m3,3491,289 259.8%   
Profit after tax Rs m10,60415,168 69.9%  
Gross profit margin %35.620.2 176.2%  
Effective tax rate %24.08.0 300.2%   
Net profit margin %26.116.1 162.2%  
BALANCE SHEET DATA
Current assets Rs m40,10560,223 66.6%   
Current liabilities Rs m6,59553,058 12.4%   
Net working cap to sales %82.57.6 1,085.1%  
Current ratio x6.11.1 535.8%  
Inventory Days Days11970 169.8%  
Debtors Days Days8188 91.5%  
Net fixed assets Rs m19,99572,984 27.4%   
Share capital Rs m5311,024 51.8%   
"Free" reserves Rs m53,04368,576 77.3%   
Net worth Rs m53,57469,600 77.0%   
Long term debt Rs m024,684 0.0%   
Total assets Rs m61,585152,207 40.5%  
Interest coverage x618.436.8 1,679.2%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.70.6 106.5%   
Return on assets %17.310.3 168.2%  
Return on equity %19.821.8 90.8%  
Return on capital %26.117.9 145.5%  
Exports to sales %00-   
Imports to sales %25.20-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m10,259NA-   
Fx inflow Rs m35,38421,280 166.3%   
Fx outflow Rs m10,39910,874 95.6%   
Net fx Rs m24,98510,406 240.1%   
CASH FLOW
From Operations Rs m11,49313,495 85.2%  
From Investments Rs m-11,372-29,103 39.1%  
From Financial Activity Rs m-9323,158 -0.4%  
Net Cashflow Rs m287,556 0.4%  

Share Holding

Indian Promoters % 52.0 74.8 69.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 8.3 142.2%  
FIIs % 19.0 5.9 322.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 11.0 156.4%  
Shareholders   31,796 44,069 72.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   TORRENT PHARMA  NATCO PHARMA  AJANTA PHARMA  SANOFI INDIA  ALEMBIC PHARMA  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Feb 16, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - NATCO PHARMA COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS